CDKN2A (p16)
- Aliases
-
- CDK4I
- CDKN2
- CDKN2A
- CDKN2A (p16)
- CMM2
- Cyclin-dependent kinase 4 inhibitor A
- Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
- INK4
- INK4a
- MTS1
- Multiple tumor suppressor 1
- p16
- p16-INK4a
- p16INK4a
- p19
- Description
- From NCBI Gene: This gene (CDKN2A) generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
Attributes
- QA State
- Curated
- Type
- Genomic
- HGNC Name
- CDKN2A
- Certifications
-
- None
- QA State for Breast
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Esophagus
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Lung
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Ovary
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Prostate
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas.
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
- Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
- Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
- The state of molecular biomarkers for the early detection of lung cancer.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.